In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
about
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitroIn vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprimIn vitro activity of Ro 23-6240, a new fluorinated 4-quinoloneChemotherapeuticsResistant traits in digital organisms do not revert preselection status despite extended deselection: implications to microbial antibiotics resistance.Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin).Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections.Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.Norfloxacin penetration into human renal and prostatic tissuesRapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in miceIn vitro activity of ciprofloxacin (Bay o 9867)Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acidCross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.Use of quinolones in the treatment of gastrointestinal infections.Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacinNorfloxacin: clinical pharmacology and clinical use.In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit.In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.In vitro and in vivo antibacterial activity of AT-2266.Antibacterial activity of norfloxacin.Norfloxacin penetration into subcutaneous tissue cage fluid in rabbits and efficacy in vivo.Comparative in vitro activity of norfloxacin and seven other antimicrobial agents against clinical isolates from urinary tract infections.High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.Bioequivalence evaluation of norfloxacin 400 mg tablets (Uroxin and Noroxin) in healthy human volunteers.Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs.In vitro studies of S-25930 and S-25932, two new 4-quinolones.Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.Comparative in vitro activity of norfloxacin against urinary tract pathogens
P2860
Q24670241-657D705F-6F01-4BEB-9469-8EE0FDE28034Q24677059-3D90B947-D13A-41C6-9C33-1E6C5EFBA0E7Q24685787-94EDA784-7845-44D5-B8F5-82CCE3C28505Q30047670-320201B0-8B80-4517-BFDF-1A33B7D87452Q33745288-90324B6A-E69D-4F00-A059-0D0DBF002D1AQ35303163-45D5877A-CB12-4125-A100-CA63C58336C2Q35568734-085034A6-70EF-4AFC-970C-3BE262945CFDQ35570242-704A9FFD-A0E8-4783-8747-DF7FD8CA8A01Q35646442-C68ADF81-0B6F-4FE4-8310-F56A37A72016Q35646512-8FD268C7-5A02-42B2-A6E9-A16F6EADB05BQ35739909-8F7B8F50-2382-4906-A12A-1CE3C11EBDB3Q35742478-3AA504F0-9DB4-42CF-8B29-567907EB9A8AQ35755165-72EF815B-23BF-4DEB-8751-3D519F02B5C9Q35757560-F61E3815-BDEE-4C1A-9882-77E49E0DB1D9Q35760077-57A9AB23-1E6B-4ACE-84B5-383F22DC91FAQ35760862-C1682AE2-9E3D-4C9A-A13A-66ED30FA288DQ37222600-E0F5994B-F676-4A78-8177-646247CEADCCQ37258777-DC47977C-DC37-4F4B-93D1-6274FD764061Q39681144-EF639CDC-7283-44F4-B0B5-3A4877D884C1Q39834358-D6486F0B-FF3B-4C7A-9431-0F7A0DA31B14Q39848971-5458F279-BF13-4A86-B138-9BD4F2D151DEQ39849489-11BA164D-AED0-4AAF-8670-D6D11AAA219DQ39850428-B9E6CD0F-9383-47A9-AC44-053C1B379C7EQ40087443-9F378C13-1FEE-480F-8507-E5261908A8A6Q40285332-F804EC9A-3745-4D5D-97A6-45DE0FA795F2Q40790774-1AFE7184-06BD-4BC7-BFD3-2CF54FC2C443Q41858315-56D29470-BE95-4E9E-BFBA-9876A5C83E4BQ41952207-9EF5E79C-9826-43AE-8FE8-7C66C7F64B19Q42928302-CB38C462-2B30-4DF2-89D2-95D00AE6DD9AQ42928386-37015F1B-83A6-4266-B1BB-69CF60F44F32Q43840994-DC955577-2708-4ACD-B7AF-4D4D8DED8D95Q44791937-CE6D20F8-E71D-4DE5-9E02-6ABF63224E58Q51551223-844A771E-B146-4B1D-BC94-E32C889DD3C5Q54008697-BF605BA9-7D3C-4CE9-A738-50DDDB919332Q54427711-2187E298-1E90-4954-A51C-3DBDBB6B8497Q54460754-AC034845-CA4B-4BFF-B504-5DF6787007F9Q57991345-18D873C7-DA88-4C12-997A-BE0DC8D30B45
P2860
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
In vitro activity of norfloxac ...... oglycosides, and trimethoprim.
@en
type
label
In vitro activity of norfloxac ...... oglycosides, and trimethoprim.
@en
prefLabel
In vitro activity of norfloxac ...... oglycosides, and trimethoprim.
@en
P2860
P356
P1476
In vitro activity of norfloxac ...... oglycosides, and trimethoprim.
@en
P2093
P2860
P356
10.1128/AAC.22.1.23
P407
P577
1982-07-01T00:00:00Z